What is Mydecine Innovations?

Mydecine Innovations Group is a biotechnology company developing first- and second-generation novel therapeutics to treat mental health and addiction disorders, including nicotine addiction and PTSD. Our global team is dedicated to efficiently advancing new treatment options in areas of significant unmet need. Focusing on psychedelic compounds and other novel molecules with therapeutic potential, the Mydecine business model combines world-class technology and drug development infrastructure, clinical trials and data outcome, and scientific and regulatory expertise. By collaborating with some of the world’s foremost authorities, the company aims to responsibly fast track the development of innovative medicines to provide patients with safe and more effective treatment options. Mydecine was founded in 2020 and is headquartered in Vancouver, British Columbia with additional offices in Denver, Colorado and in Leiden, Netherlands.

Where is Mydecine headquartered?

The company is headquartered in Vancouver, British Columbia with additional offices in Denver, Colorado and in Leiden, Netherlands.

Who are Mydecine’s top executives?

Leadership team

When did Mydecine become a public company?

Mydecine became listed on CSE on August 18, 2014, the Company was uplisted to the NEO Exchange on March 23, 2021.

What exchange does the stock trade on and what is the stock ticker symbol?

Mydecine is traded on the NEO exchange in Canada (MYCO), the OTC market in the United States (MYCOF), and the FSE exchange in Germany (0NFA).

How do I invest in Mydecine?

You can purchase shares in the Company through a registered broker-dealer of your choice. You cannot purchase units directly from the Company. For information about investing in stocks, you may want to consult a financial professional to explain to you the risks and suitability when investing.

Does Mydecine offer a Direct Stock Purchase Plan (DSPP or DRIP)?

We do not offer a direct stock purchase or dividend reinvestment program.

Does Mydecine pay a dividend?

Mydecine does not anticipate paying any cash dividends in the foreseeable future.

When is the Company's fiscal year end?

Our fiscal year end is December 31.

Who is Mydecine's independent auditor?

MNP LLP

Address: Suite 2000, 330 5th Ave. S.W., Calgary, AB, T2P 0L4

Email: Maruf Raza – maruf.raza@mnp.ca

Tel: +1 403-444-0150

Who is Mydecine’s transfer agent?

National Securities Administrators Ltd

Where can I get a copy of materials filed?

Our public securities filings are available on www.sedar.com.

What analysts have initiated coverage on Mydecine?

Canaccord Genuity Coverage by Matthew Pepler September 13, 2021

Roth Capital Partners Coverage by Elmer Prios, Ph.D. November 16, 2021

MAXIM Group Coverage by Jason McCarthy, Ph. D. October 5, 2021

Proactive Investors by Ed Stacey, CFA December 20, 2021

**Please note Mydecine does not endorse the reports of analysts and have had no input into the preparation of the reports

Do you have another question that hasn't been answered?

Please submit investor questions here.